Selected research
Industry Research
Opioid Antagonist Industry Research Report 2026
Market perspective
The global Opioid Antagonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Opioid Antagonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Opioid Antagonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Opioid Antagonist include Titan Pharmaceuticals, AstraZeneca, Shionogi, Orexo, Opiant Pharmaceuticals, Indivior, Hikma Pharmaceuticals, Collegium Pharmaceutical and Camurus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Opioid Antagonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Opioid Antagonist Market by Company
Titan Pharmaceuticals
AstraZeneca
Shionogi
Orexo
Opiant Pharmaceuticals
Indivior
Hikma Pharmaceuticals
Collegium Pharmaceutical
Camurus
BioDelivery Sciences International
Alkermes
Acura Pharmaceuticals
Opioid Antagonist Segment by Type
Oral
Parenteral
Opioid Antagonist Segment by Application
Hospitals
Clinics
Others
Opioid Antagonist Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Opioid Antagonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Opioid Antagonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Opioid Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Parenteral
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Titan Pharmaceuticals
- AstraZeneca
- Shionogi
- Orexo
- Opiant Pharmaceuticals
- Indivior
- Hikma Pharmaceuticals
- Collegium Pharmaceutical
- Camurus
- BioDelivery Sciences International
- Alkermes
- Acura Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Opioid Antagonist Market Size (2021-2032)
- 2.2.2 Global Opioid Antagonist Sales (2021-2032)
- 2.2.3 Global Opioid Antagonist Market Average Price (2021-2032)
- 2.3 Opioid Antagonist by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Parenteral
- 2.4 Opioid Antagonist by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Opioid Antagonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Opioid Antagonist Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Opioid Antagonist Revenue of Manufacturers (2021-2026)
- 3.4 Global Opioid Antagonist Average Price by Manufacturers (2021-2026)
- 3.5 Global Opioid Antagonist Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Opioid Antagonist, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Opioid Antagonist, Product Type & Application
- 3.8 Global Manufacturers of Opioid Antagonist, Established Date
- 3.9 Global Opioid Antagonist Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Titan Pharmaceuticals
- 4.1.1 Titan Pharmaceuticals Company Information
- 4.1.2 Titan Pharmaceuticals Business Overview
- 4.1.3 Titan Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Titan Pharmaceuticals Opioid Antagonist Product Portfolio
- 4.1.5 Titan Pharmaceuticals Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Opioid Antagonist Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Shionogi
- 4.3.1 Shionogi Company Information
- 4.3.2 Shionogi Business Overview
- 4.3.3 Shionogi Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shionogi Opioid Antagonist Product Portfolio
- 4.3.5 Shionogi Recent Developments
- 4.4 Orexo
- 4.4.1 Orexo Company Information
- 4.4.2 Orexo Business Overview
- 4.4.3 Orexo Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Orexo Opioid Antagonist Product Portfolio
- 4.4.5 Orexo Recent Developments
- 4.5 Opiant Pharmaceuticals
- 4.5.1 Opiant Pharmaceuticals Company Information
- 4.5.2 Opiant Pharmaceuticals Business Overview
- 4.5.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Opiant Pharmaceuticals Opioid Antagonist Product Portfolio
- 4.5.5 Opiant Pharmaceuticals Recent Developments
- 4.6 Indivior
- 4.6.1 Indivior Company Information
- 4.6.2 Indivior Business Overview
- 4.6.3 Indivior Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Indivior Opioid Antagonist Product Portfolio
- 4.6.5 Indivior Recent Developments
- 4.7 Hikma Pharmaceuticals
- 4.7.1 Hikma Pharmaceuticals Company Information
- 4.7.2 Hikma Pharmaceuticals Business Overview
- 4.7.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hikma Pharmaceuticals Opioid Antagonist Product Portfolio
- 4.7.5 Hikma Pharmaceuticals Recent Developments
- 4.8 Collegium Pharmaceutical
- 4.8.1 Collegium Pharmaceutical Company Information
- 4.8.2 Collegium Pharmaceutical Business Overview
- 4.8.3 Collegium Pharmaceutical Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Collegium Pharmaceutical Opioid Antagonist Product Portfolio
- 4.8.5 Collegium Pharmaceutical Recent Developments
- 4.9 Camurus
- 4.9.1 Camurus Company Information
- 4.9.2 Camurus Business Overview
- 4.9.3 Camurus Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Camurus Opioid Antagonist Product Portfolio
- 4.9.5 Camurus Recent Developments
- 4.10 BioDelivery Sciences International
- 4.10.1 BioDelivery Sciences International Company Information
- 4.10.2 BioDelivery Sciences International Business Overview
- 4.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 BioDelivery Sciences International Opioid Antagonist Product Portfolio
- 4.10.5 BioDelivery Sciences International Recent Developments
- 4.11 Alkermes
- 4.11.1 Alkermes Company Information
- 4.11.2 Alkermes Business Overview
- 4.11.3 Alkermes Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Alkermes Opioid Antagonist Product Portfolio
- 4.11.5 Alkermes Recent Developments
- 4.12 Acura Pharmaceuticals
- 4.12.1 Acura Pharmaceuticals Company Information
- 4.12.2 Acura Pharmaceuticals Business Overview
- 4.12.3 Acura Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Acura Pharmaceuticals Opioid Antagonist Product Portfolio
- 4.12.5 Acura Pharmaceuticals Recent Developments
5 Global Opioid Antagonist Market Scenario by Region
- 5.1 Global Opioid Antagonist Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Opioid Antagonist Sales by Region: 2021-2032
- 5.2.1 Global Opioid Antagonist Sales by Region: 2021-2026
- 5.2.2 Global Opioid Antagonist Sales by Region: 2027-2032
- 5.3 Global Opioid Antagonist Revenue by Region: 2021-2032
- 5.3.1 Global Opioid Antagonist Revenue by Region: 2021-2026
- 5.3.2 Global Opioid Antagonist Revenue by Region: 2027-2032
- 5.4 North America Opioid Antagonist Market Facts & Figures by Country
- 5.4.1 North America Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Opioid Antagonist Sales by Country (2021-2032)
- 5.4.3 North America Opioid Antagonist Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Opioid Antagonist Market Facts & Figures by Country
- 5.5.1 Europe Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Opioid Antagonist Sales by Country (2021-2032)
- 5.5.3 Europe Opioid Antagonist Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Opioid Antagonist Market Facts & Figures by Country
- 5.6.1 Asia Pacific Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Opioid Antagonist Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Opioid Antagonist Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Opioid Antagonist Market Facts & Figures by Country
- 5.7.1 South America Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Opioid Antagonist Sales by Country (2021-2032)
- 5.7.3 South America Opioid Antagonist Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Opioid Antagonist Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Opioid Antagonist Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Opioid Antagonist Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Opioid Antagonist Sales by Type (2021-2032)
- 6.1.1 Global Opioid Antagonist Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Opioid Antagonist Sales Market Share by Type (2021-2032)
- 6.2 Global Opioid Antagonist Revenue by Type (2021-2032)
- 6.2.1 Global Opioid Antagonist Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Opioid Antagonist Revenue Market Share by Type (2021-2032)
- 6.3 Global Opioid Antagonist Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Opioid Antagonist Sales by Application (2021-2032)
- 7.1.1 Global Opioid Antagonist Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Opioid Antagonist Sales Market Share by Application (2021-2032)
- 7.2 Global Opioid Antagonist Revenue by Application (2021-2032)
- 7.2.1 Global Opioid Antagonist Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Opioid Antagonist Revenue Market Share by Application (2021-2032)
- 7.3 Global Opioid Antagonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Opioid Antagonist Value Chain Analysis
- 8.1.1 Opioid Antagonist Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Opioid Antagonist Production Mode & Process
- 8.2 Opioid Antagonist Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Opioid Antagonist Distributors
- 8.2.3 Opioid Antagonist Customers
9 Global Opioid Antagonist Analyzing Market Dynamics
- 9.1 Opioid Antagonist Industry Trends
- 9.2 Opioid Antagonist Industry Drivers
- 9.3 Opioid Antagonist Industry Opportunities and Challenges
- 9.4 Opioid Antagonist Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst